Ultimovacs (ULTI) småprat 1

[Fornybar]

Får du jobbet noe, @Forsk ?

[Rolsu]

Fortsetter vi opp eller er det pump og dump svensker på news?

[Rolsu]

Blir spennende å se

[enurs]

Æ har alltid ment svensker er dumme men når de nå hamstrer Ultimo må man kanskje vurdere om…

[Rolsu]

Blir uansett fint med en verifisering av de gode resultatene. Håper vi

[h3nk1]

@Fornybar

Får du jobbet noe, @Forsk ?

Edit: forbedring(er)

[Varm-buffet]

#denfølelsen når aksjen er så sterk som den er om dagen og man vurderer å ta gevinsten - for så å titte på det fundamentale i selskapet og bare være «velkommen etter, dette er en fornuftig reprising»

Det er lett å bli revet med, men det føles bare så…. riktig at Ultimovacs trader oppover.

[TekBot]

Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

• First patient in second cohort dosed with 400 ?g of TET vaccine
  • DSMB found no safety concerns for first cohort of three patients at 40 ?g
    dose
    …

Vis børsmeldingen

Oslo, 1 October 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage
leader in immune stimulatory vaccines for cancer, announced it has started
dosing of the second cohort in the Phase I TENDU trial, evaluating the Company’s
Tetanus-Epitope Targeting (TET)-platform.

The TENDU clinical trial, conducted at the Oslo University Hospital, is a first-
in-human, dose-escalation study designed to generate initial safety and immune
activation data for a prostate cancer-specific therapeutic TET-based vaccine in
prostate cancer patients who have relapsed following radical prostatectomy.
Three different and escalating doses of the TET vaccine are being investigated
in the study, 40, 400 and 960 ?g. Dosing of the 400 ?g cohort has now been
initiated.

“We are pleased to continue to advance this Phase 1 trial evaluating Ultimovacs’
TET platform in prostate cancer. The 400 ?g dose, which we are now
investigating, is in a clinically relevant range predicted by preclinical
studies,” said Jens Bjørheim, Chief Medical Officer of Ultimovacs. “We are
looking forward to continuing to investigate this new therapeutic prostate
cancer vaccine, which has the potential to address a significant medical need by
reducing recurrence of the disease. The TENDU study is also important for us as
a way of generating initial data on the novel TET platform, as we further expand
the Ultimovacs pipeline.”

The TET platform allows for the production of multiple therapeutic cancer
vaccines that can be used to strengthen and increase T cell responses to cancer
cells by targeting antigens that are specific to one type of cancer or common to
many tumor types. The vaccine used in the TENDU trial contains prostate cancer-
specific antigens. By combining cancer antigens and the vaccine adjuvant in the
same molecule, this unique platform can generate vaccine candidates with a
beneficial safety and administration profile, presenting an opportunity to treat
patients at an early stage of their disease.

                                ==ENDS==

About the TET-platform
The Tetanus-Epitope Targeting(TET)-platform offers an approach to strengthen and
increase T cell responses against cancer-specific peptides by combining cancer-
specific antigens and vaccine adjuvant in the same conjugated molecule, allowing
for a beneficial safety profile and simplifying administration. The platform
generates new, first-in-class cancer vaccine candidates that harness pre-
existing antibody responses resulting from standard tetanus vaccinations. TET
vaccine candidates can be tailored to many types of cancer.

About TENDU
The TENDU clinical trial (NCT04701021) is a first-in-human, Phase I study and
the first clinical trial of a vaccine from Ultimovacs’ Tetanus-Epitope Targeting
(TET)-platform. The trial is being conducted at the Oslo University Hospital,
Norway, and evaluates the safety of the vaccine in prostate cancer patients who
have relapsed after radical prostatectomy. The primary objective of the study is
to evaluate the safety and tolerability of three different doses of the vaccine.
Patients will receive the vaccine prior to obtaining standard-of-care treatment
consisting of radiation and antihormone therapy and will be followed for 6
months after the last dose of the vaccine to assess immunological responses such
as the activation of T cells and anti-tumor activity.

About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of
cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human
telomerase (hTERT), present in over 80% of cancers in all stages of tumor
growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper
T cells to the tumor to activate an immune system cascade and increase anti-
tumor responses. With a broad Phase II program, Ultimovacs aims to clinically
demonstrate UV1’s impact in multiple cancer types in combination with other
immunotherapies. Ultimovacs’ second technology approach, based on the
proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific
peptides and adjuvant in the same molecule and entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com (mailto:hans.eid@ultimovacs.com)
Phone: +47 482 48632

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Hans Vassgård Eid, CFO at
Ultimovacs ASA, on 1 October, 2021 at 12:30 CET.

Kilde

[anon6994212]

Selv concorde smiler nå. 157,2 Gratla til alle inne å en stor takk til «innsiderene» For et forum

[theroger]

Ultimovacs har startet dosering

Ultimovacs begins dosing of 2nd cohort in Phase I TENDU study - Nordic Life...

[Otard]

Allerede???
UV1 virker på >85% av alle krefttyper. Tar TET plattformen resten da ell?

Det er nesten så jeg må poste denne igjen; Only U er det man trenger i portefølgen:

Only You (And You Alone)

[breakout]

Ive been buying Ultimovacs since march last year… wish I bought more… my best stock to date. I had TP set to 350 Im thinking to change to 50% 350 and leave the rest to 650-1000kr

[vegar_beider]

[AndyO]

Det var voldsomt til reaksjon i dag da.

[nhy1024]

@TekBot

The 400 ?g dose, which we are now investigating

“Artig” hvordan alle medier, inkludert FA ikke får med seg at dette er mikrogram, ikke gram - som er 1 million ganger feil…

Jøje meg, nesten en halv kilo, gitt…

Sånn går det når den originale pressemeldingen bruker “fancy” Unicode tegn som ingen klarer å konvertere - her er originalen:

[nhy1024]

Jeg fikk TDN til å rette det ihvertfall

[anon6994212]

1 av 2 maskiner siste 3 måneder

[Fartin]

Nøyaktig 1 år siden jeg satte barnetrygden i noen ultimovacs aksjer til datra…

[Storezlem]

Herlig utvikling på Ultimovacs…

Nesten 500% opp siden Oktober 2019, godt enkelte unngår shorting og motstand…

Gjelsten og Hagen & co

Oslo børs ass…

Mvh

[h3nk1]

@h3nk1

Til melodien av Øystein Sunde sin «Hva var det jeg sa» er det nettopp lagt til et nytt siste vers:

Øystein Sunde - Hva var det jeg sa

Profeten han står der, med mobben i handa, og knatrer ut enda enn Tweet: «KLP bør få HIV, og Inven2 ligget stiv - for det er på tide med reprising nå».

Så han hauser på TI og hater Savepig på chatten, og når omsider Jansrud og Dæhlie tar inngang med Tvenge, så skriver han i capslock nå:

HVA VAR DET JEG SA? HVA VAR’E JEG SA? NÅ KAN DERE SITTE Å SE KURSEN STIKKE SIROMPA NEPER. FOR HER REGJERER JEG.

HVA VAR DET JEG SA? HVA VAR’E JEG SA? JEG VAR ALLTID PROFET, NÅ ER JEG GUD I TILLEGG. KOM TIL MEG, DISIPLER.

HVA VAR DET JEG SA.

Volummussolini er fornøyd. Reprising har funnet sted. Svenskene er happy. Chatten er forundret.

Mvh.

Edit:

Om bare dollaren holder seg nå, så blir det bra.